Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer

References

• Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, based on November 2018 SEER data submission, posted to the SEER website, April 2019. https://seer.cancer.gov/archive/csr/1975_2016/
   Google Scholar
• Agostinetto E, Eiger D, Punie K, et al. Emerging therapeutics for patients with triple-negative breast cancer. Curr Oncol Rep. 2021;23(5):57.
   PubMed Web of Science ®Google Scholar
• Mehanna J, Haddad FG, Eid R, et al. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health. 2019;11:431–437.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767.
   PubMed Web of Science ®Google Scholar
• Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–1698.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Tagliamento M, Agostinetto E, Borea R, et al. Vista: a promising target for cancer immunotherapy? ImmunoTargets Ther. 2021;10:185–200.
   PubMed Web of Science ®Google Scholar
• Cimino-Mathews A, Ye X, Meeker A, et al. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol. 2013;44(10):2055–2063.
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(7):860–867.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Losurdo A, De Sanctis R, Fernandes B, et al. Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice. Sci Rep. 2020;10(1):20100.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, V PA, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4): 361 LP - 370.
   PubMed Web of Science ®Google Scholar
• Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–241.
   PubMed Web of Science ®Google Scholar
• Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–120.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418): 61–70. DOI:https://doi.org/10.1038/nature11412.
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of Atezolizumab therapy for patients with metastatic triple-negative breast cancer: a Phase 1 study. JAMA Oncol. 2019;5(1):74–82.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. DOI:https://doi.org/10.1056/NEJMoa1809615.
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59.
   PubMed Web of Science ®Google Scholar
• Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: iMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983–993.
   PubMed Web of Science ®Google Scholar
• Cortés J, Lipatov O, S-A I, et al. KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann Oncol. 2019;30:v859–v860.
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(8):994–1004.
   PubMed Web of Science ®Google Scholar
• Franzoi MA, de Azambuja E. Atezolizumab in metastatic triple-negative breast cancer: iMpassion130 and 131 trials - how to explain different results? ESMO open. 2020;5(6):e001112.
   PubMed Web of Science ®Google Scholar
• Emens LA, Goldstein LD, Schmid P, et al. The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): iMpassion130. J Clin Oncol. 2021;39(15_suppl):1006.
   Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol. 2020;38(15_suppl):1000.
   Google Scholar
• Rugo H, Cortes, J, Cescon, DW, et al. LBA16 - KEYNOTE-355: final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Ann Oncol. 2021;32:S1283–S1346.https://doi.org/10.1016/annonc/annonc741.
   Google Scholar
• Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(21):2460–2467.
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404.
   PubMed Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405–411.
   PubMed Web of Science ®Google Scholar
• Winer EP, Lipatov O, S-A I, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499–511.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/Mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(1):1–10.
   PubMed Web of Science ®Google Scholar
• Alva AS, Mangat PK, Garrett-Mayer E, et al. Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol. 2021;39(22):2443–2451.
   PubMed Web of Science ®Google Scholar
• Bachelot T, Filleron T, Bieche I, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat Med. 2021;27(2):250–255.
   PubMed Web of Science ®Google Scholar
• Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(5):569–581.
   PubMed Web of Science ®Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing Phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–684.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. VP7-2021: KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol. 2021;32(9):1198–1200.
   Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–567. DOI:https://doi.org/10.1056/NEJMoa2112651.
   PubMed Web of Science ®Google Scholar
• Foldi J, Silber A, Reisenbichler E, et al. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer. 2021;7(1):9.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tri. Lancet. 2020;396(10257):1090–1100.
   PubMed Web of Science ®Google Scholar
• Poggio F, Tagliamento M, Ceppi M, et al. Adding a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer: the end of the debate. Ann Oncol. 2021;33:347–349.
   PubMed Web of Science ®Google Scholar
• Gianni L, Huang C-S, Egle D, et al. Abstract GS3-04: pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. 2020.
   Google Scholar
• Bianchini G, Huang C-S, Egle D, et al. LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol. 2020;31:S1145–S1146.
   Web of Science ®Google Scholar
• Yam C, Mittendorf EA, Sun R, et al. Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC). J Clin Oncol. 2021;39(15_suppl):592.
   Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–1288.
   PubMed Web of Science ®Google Scholar
• Loibl S, Schneeweiss A, Huober JB, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol. 2021;39(15_suppl):506.
   Google Scholar
• Saji S, McArthur HL, Ignatiadis M, et al. ALEXANDRA/IMpassion030: a phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer. J Clin Oncol. 2021;39(15_suppl): TPS597–TPS597.
   Web of Science ®Google Scholar
• De La Motte Rouge T, Frenel J-S, Borcoman E, et al. 274P metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): efficacy and safety results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study. Ann Oncol. 2021;32:S482–S483.
   Web of Science ®Google Scholar
• Carey LA, Pierga J-Y, Kümmel S, et al. 275P A phase II study of LAG525 in combination with spartalizumab (PDR001), PDR001 and carboplatin (Carbo), or Carbo, as first- or second-line therapy in patients (Pts) with advanced (Adv) triple-negative breast cancer (tnbc). Ann Oncol. 2021;32:S483–S484.
   Web of Science ®Google Scholar
• Patel MR, Naing A, Burris IIIHA, et al. A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies. J Clin Oncol. 2021;39(15_suppl):2624.
   Web of Science ®Google Scholar
• DiMascio L, Thakkar D, Gandhi N, et al. HMBD-002 is a novel, neutralizing, anti-Vista antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab. J Clin Oncol. 2021;39(15_suppl):e14569–e14569.
   Web of Science ®Google Scholar
• de Aguiar RB, de Moraes JZ. Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors. Front Immunol. 2019;10:1023.
   PubMed Web of Science ®Google Scholar
• Jiang Y-Z, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021;31(2):178–186.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhimin S, Wang Z, et al. Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): a prospective, single-arm, phase 2 study. J Clin Oncol. 2021;39(15_suppl):1007.
   Web of Science ®Google Scholar
• Ozaki Y, Matsumoto K, Takahashi M, et al. Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial). J Clin Oncol. 2018;36(15_suppl): TPS1110–TPS1110.
   Web of Science ®Google Scholar
• Wang J, Xu B, Sun T, et al. A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer. J Clin Oncol. 2021;39(15_suppl):1074.
   Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–1541. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.1074.
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Keenan TE, Li T, et al. Saci-IO TNBC: randomized phase II trial of sacituzumab govitecan (SG) ± pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2021;39(15_suppl): TPS1106–TPS1106.
   Google Scholar
• Han H, Diab S, Alemany C, et al. Abstract PD1-06: open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer. In: Cancer research. Vol. 80. American Association for Cancer Research (AACR); 2020. p. D1-06-PD1-06. DOI:https://doi.org/10.1158/1538-7445.sabcs19-pd1-06.
   Google Scholar
• Domchek SM, Postel-Vinay S, Im S-A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–1164.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132–1140.
   PubMed Web of Science ®Google Scholar
• Chan ASH, Jonas AB, Qiu X, et al. Imprime PGG-mediated anti-cancer immune activation requires immune complex formation. PLoS One. 2016;11(11):e0165909.
   PubMed Web of Science ®Google Scholar
• O’Day S, Borges VF, Chmielowski B, et al. An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (P) in previously treated metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2019;37(15_suppl):2550.
   Web of Science ®Google Scholar
• Buisseret L, Pommey S, Allard B, et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(4):1056–1062.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A. 2013;110(36):14711–14716.
   PubMed Web of Science ®Google Scholar
• Eiger D, Maurer C, Brandao M, et al. 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020;31:S386–S387.
   Web of Science ®Google Scholar
• Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol. 2008;19(4):669–674.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Kim SB, Zvirbule Ž, et al. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(5):652–660.
   PubMed Web of Science ®Google Scholar
• Chien AJ, Rahmaputri S, Dittrich HF, et al. A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC). J Clin Oncol. 2019;37(15_suppl):1072.
   Web of Science ®Google Scholar
• Sharma P, Abramson VG, O’Dea A, et al. Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC). J Clin Oncol. 2021;39(15_suppl):1076.
   Web of Science ®Google Scholar
• O’Shaughnessy J, Moroose RL, Babu S, et al. Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC). J Clin Oncol. 2020;38(15_suppl):1014.
   Google Scholar
• Roussos Torres ET, Rafie C, Wang C, et al. Phase I study of entinostat and Nivolumab with or without Ipilimumab in advanced solid tumors (ETCTN-9844). Clin Cancer Res. 2021;27(21): 5828 LP - 5837.
   PubMed Web of Science ®Google Scholar
• Calmeiro J, Carrascal MA, Tavares AR, et al. Dendritic cell vaccines for cancer Immunotherapy: the role of human conventional Type 1 dendritic cells. Pharmaceutics. 2020;12(2):158.
   PubMed Web of Science ®Google Scholar
• Ortego I, Vizcay AM, De La Cruz S, et al. Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression. J Clin Oncol. 2021;39(15_suppl):585.
   Web of Science ®Google Scholar
• Soliman HH, Han HS, Hogue D, et al. A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer. J Clin Oncol. 2021;39(15_suppl):578.
   Web of Science ®Google Scholar
• Chien AJ, Soliman HH, Ewing CA, et al. Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: results from the I-SPY 2 trial. J Clin Oncol. 2021;39(15_suppl):508.
   Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Nakasone ES, Hurvitz SA, McCann KE. Harnessing the immune system in the battle against breast cancer. Drugs Context. 2018;7:212520.
   PubMedGoogle Scholar
• Gatti-Mays ME, Balko JM, Gameiro SR, et al. If we build it they will come: targeting the immune response to breast cancer. Npj Breast Cancer. 2019;5(1):37.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–362.
   PubMed Web of Science ®Google Scholar
• Loi S, Winer E, Lipatov O, et al. Abstract PD5-03: relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2020;80(4 Supplement): D5-03 LP-PD5-03.
   PubMed Web of Science ®Google Scholar
• Shohdy KS, Almeldin DS, Ghaly R, et al. Prognostic impact of cytotoxic CD4 T cells in tumor immune microenvironment of patients with breast cancer. J Immunother Precis Oncol. 2021;5(1):7–9.
   PubMedGoogle Scholar
• Wr A, Orion T, Rosalin C, et al. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity. Sci Immunol. 2021;6(64):eabj8825.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690.
   PubMed Web of Science ®Google Scholar
• Bai R, Lv Z, Xu D, et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020;8(1):34.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res an off J Am Assoc Cancer Res. 2009;15(23):7412–7420.
   PubMed Web of Science ®Google Scholar
• Hoos A, Eggermont AMM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388–1397.
   PubMed Web of Science ®Google Scholar
• Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(Suppl 8):viii47–52.
   PubMed Web of Science ®Google Scholar
• Berruti A, Amoroso V, Gallo F, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(34):3883–3891.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Smith A, Shaghayegh G, Menzies AM, et al. Duration of immunotherapy – should we continue ad infinitum? Intern Med J. 2020;50(7):865–868.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy M, Lenehan JG, Maleki Vareki S. Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges. J Natl Cancer Inst. 2021;113(7):823–832.
   PubMedGoogle Scholar
• Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(2):219–235.
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–928.
   PubMed Web of Science ®Google Scholar
• Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497–1508.
   PubMed Web of Science ®Google Scholar
• Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159.
   PubMed Web of Science ®Google Scholar
• Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–2405.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–iv142.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines(†). Ann Oncol Off J Eur Soc Med Oncol. 2020;31(12):1664–1678.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Amant F, Braat D, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4):hoaa052.
   PubMedGoogle Scholar
• Garutti M, Lambertini M, Puglisi F. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO open. 2021;6(5):100276.
   PubMed Web of Science ®Google Scholar
• Duma N, Lambertini M. It is time to talk about fertility and immunotherapy. Oncologist. 2020;25(4):277–278.
   PubMed Web of Science ®Google Scholar
• Borgers JSW, Heimovaara JH, Cardonick E, et al. Immunotherapy for cancer treatment during pregnancy. Lancet Oncol. 2021;22(12):e550–e561.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Clatot F, Demeestere I, et al. Cancer survivorship: reproductive health outcomes should be included in standard toxicity assessments. Eur J Cancer. 2021;144:310–316.
   PubMed Web of Science ®Google Scholar
• Mortensen MJ, Oatman O, Azadi A, et al. An update on immune checkpoint inhibitor-related hypophysitis. US Endocrinol. 2020;16:117. DOI:https://doi.org/10.17925/USE.2020.16.2.117.
   Google Scholar